You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 3597 results
  1. Risperidone Subcutaneous Implant

    SBC: DELPOR INC            Topic: 101

    The objective of the proposed study is to develop a subcutaneous implant of risperidone that provides consistent therapeutic blood levels of the drug for 6 months after a single administration. The device is implanted during a simple, 10-minute, in-office procedure with local anesthetic. The benefits of the product include improved medication adherence, fewer relapses, ability to withdraw the medi ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a rapid response nucleic acid vaccine strategy for coronavirusepidemics

    SBC: ORLANCE, INC            Topic: NIAID

    ABSTRACT In response to the emerging COVID-19 (SARS-CoV-2) pandemic, this supplement proposal to R44 AI138733- 01 will leverage our cutting-edge nucleic acid vaccine strategies, some of which that were developed under this parent grant. Here, we request supplement funding to develop candidate COVID-19 DNA and RNA vaccines expressing optimally designed immunogens for the SARS-CoV-2 spike protein. N ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Human Neural Cell Exosomes as a Therapeutic Treatment for Stroke

    SBC: ARUNA BIO, INC.            Topic: NINDS

    Project Summary Cytoprotective and restorative treatments for acute ischemic stroke (AIS) is a major unmet medical need. The current standard of care for stroke patients is centered on recanalization efforts to restore cerebral perfusion through the administration of tissue plasminogen activator (tPA) or mechanical thrombectomy. However, despite a recent extension of recanalization treatment windo ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Populating MPS database with data from multi-organ, human-on-a-chip microphysiological systems

    SBC: HESPEROS, INC            Topic: 100

    Project Summary/Abstract: As stated in the Notice of Special Interest announcement, there is a need to populate the recently established MPS database with existing data generated by organ-on-a-chip systems. Having a centralized, public database with data from all available MPS systems will accelerate development and acceptance of the technology ultimately bringing better therapies to patients fast ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. An Innovative Platform for Objective Monitoring of Instrumental Activities of Daily Living

    SBC: BIOSENSICS LLC            Topic: NIA

    With a Phase I/II STTR grant award from NIA, BioSensics in collaboration with Baylor College of Medicine (BCM) successfully developed and commercialized an advanced physical activity monitoring system (PAMSys™) for older adults. PAMSys enables continuous remote monitoring of physical activity, fall risk, and fall incidents. The fall detection technology of PAMSys has become the gold standard in ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. A Single-Cell Proteomic instrument for Predictive Product Quality Check in Autologous CAR-T Immunotherapies

    SBC: ISOPLEXIS CORPORATION            Topic: 102

    While CAR-T therapies have advanced in the clinic, there are still two specific issues using these breakthrough therapies for blood cancers: Durable responses in patients are only at 30-50% and Cytokine Release Syndrome occurs in 60-90% of treated patients. These limitations, for a drug that costs as much as $500,000, may cost an additional $250,000+ for treating adverse events leading to caution ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. An Integrated CT-based Image-Guided Neurosurgical System

    SBC: Xoran Technologies LLC            Topic: 102

    An Integrated CT-based Image-Guided Neurosurgical System In this SBIR Phase IIb proposal Xoran intends to commercialize a compact and affordable, yet highly- functional, system to provide real time image updates and navigation guidance in support of minimally invasive cranial and spinal neurosurgical procedures. The effort builds on previously developed compact and portable flat-panel Computed Tom ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Robot-Assisted Cognitive Training for Socially Isolated Older Adults with Mild Cognitive Impairment

    SBC: Applied Universal Dynamics, Corp.            Topic: NIA

    This project will develop a Socially-Assistive Robot (SAR) to provide cognitive training, in the form of learning to play the piano, to improve cognitive functioning and reduce feelings of loneliness in socially-isolated older adults. The SAR will administer cognitive training via guided practice on a set of standard piano lesson tasks designed to reflect particular cognitive functions: memory, at ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. A Phase 2b Clinical Trial to Study the Efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) to Treat Aging Frailty

    SBC: Longeveron LLC            Topic: NIA

    Aging Frailty is a biologically driven geriatric syndrome of multisystem physiological decline that is distinct from normal aging and disproportionately increases vulnerability to adverse clinical outcomes. Frailty has an overall prevalence of 10% of those 65 years and older, and there is growing awareness in the geriatric community to diagnose and treat this condition, as it is not an inevitable ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Developing and Evaluating In-Home Supportive Technology for Dementia Caregivers

    SBC: PEOPLE POWER COMPANY            Topic: NIA

    AbstractCaring for a loved one with Alzheimer’s disease, frontotemporal dementia, or another neurodegenerative disease is a highly meaningful part of family life. However, the associated burden and strain can have adverse effects on caregivers including mental and physical health problems, reduced well-being, and increased mortality. These effects, in turn, can compromise care quality and shorte ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government